Alector Ends Latozinemab Continuation Study: Reading the Signals for ALEC Investors

Alector (ALEC) announced an update on their ongoing clinical study.

Alector’s Latozinemab Continuation Study Ends: What Investors Should Know

Study Overview: The study, formally titled “A Continuation Study of Latozinemab in Participants With Neurodegenerative Disease,” was designed to keep giving Alector’s drug latozinemab (AL001) to patients who had already taken part in earlier trials. The main goal was to maintain access to treatment and gather additional safety and longer-term use information in people with neurodegenerative diseases, an area with high unmet medical need.

Intervention/Treatment: The intervention is latozinemab, a drug given by intravenous (IV) infusion. Patients received the drug every four weeks at a weight-based dose. The purpose was to continue testing whether ongoing treatment could be used safely over time in patients with neurodegenerative conditions.

Study Design: This was an interventional Phase 3 continuation study with a single treatment group. All enrolled participants received latozinemab; there was no placebo or comparison arm. The trial was open label, meaning both doctors and patients knew they were getting the drug. The primary intent was treatment, not diagnosis or prevention.

Study Timeline: The trial was first submitted in October 2023, reflecting when the continuation plan and protocol were brought forward. It has since been marked as terminated, signaling that dosing and follow-up under this extension protocol have stopped. The most recent update was posted on January 20, 2026, which is the key date investors should note as it confirms the latest status and any changes to the study’s conduct and scope.

Market Implications: Termination of a Phase 3 continuation study can weigh on sentiment toward Alector (ALEC), as investors often see ongoing extension studies as a sign of confidence in a drug’s long-term profile and commercial potential. The end of this study may raise questions about latozinemab’s future path, label prospects, or strategic priority within Alector’s pipeline. Competitors in neurodegeneration, including larger players with multiple assets and more diversified revenue, may look relatively more secure in this context. For ALEC, the market will focus on management’s explanation, remaining late-stage assets, and cash runway. Short term, the update could add volatility and pressure to the stock until investors better understand how this fits with the broader clinical and partnership strategy.

The study has been updated as terminated, and further details are available on the ClinicalTrials.gov portal for NCT06111014.

To learn more about ALEC’s potential, visit the Alector drug pipeline page.